ArticleEClinicalMedicine2023

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial.

Suad Hannawi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.